Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) and its
subsidiary, Macrophage Therapeutics, Inc., today announced that
four presentations of Manocept™ data from Kaposi’s Sarcoma (KS)
studies are scheduled at the 18th International Workshop
on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents
in Hollywood, Florida from June 30 - July 3, 2015. This research
highlights a very likely new approach to the origin of KS supported
by preclinical and clinical imaging studies. In addition, data will
be presented demonstrating the therapeutic potential for Manocept
therapeutic conjugates. MT1001 is a proprietary agent designed to
target cells expressing the mannose receptor (CD206) and destroy
the cell and its contents. Data will be presented demonstrating
MT1001’s ability to target KS and KS tumor-associated macrophages
by selectively binding to CD206. Details of the presentations are
listed below.
Poster Session:
Date:
July 1, 2015
Title:
In Vivo Localization and Potential for Therapeutic Targeting of
Kaposi’s Sarcoma (KS) With A Novel CD206 Localizing Agent
Authors:
M McGratha,b*, J Zhanga, T Maurera, S
Behra, B Abbruzzesec, J Sandersc, P Braccia,b, FO Copec
(*Presenter)
aUniv of California-San Francisco; bAIDS
& Cancer Specimen Resource, SFGH c Navidea/Macrophage
Therapeutics
Poster Session:
Date:
July 1, 2015
Title:
Imaging and Therapeutic Potential for
Kaposi’s Sarcoma (KS) In Non-Cutaneous Foci with a Novel CD206
Localizing Agent
Authors:
B Abbruzzesea*, FO Copea, J Zhangb, T
Maurerb, S Behrb, J Sandersa, P Braccib,c, M McGrathb,c
(*Presenter)
aNavidea/Macrophage Therapeutics; bUniv of
California-San Francisco; cAIDS & Cancer Specimen Resource,
SFGH
Poster Session:
Date:
July 1, 2015
Title:
Kaposi’s Sarcoma (KS) is a Macrophage (MO)
Tumor Resulting from a Fusion CD206+MOs and Lymphatic
Endothelium
Authors:
FO Copea*, J Zhangb, T Maurerb, B
Abbruzzesea, J Sandersa, S Behrb, P Braccib,c, M McGrathb,c
(*Presenter)
aNavidea/Macrophage Therapeutics; bUniv of
California-San Francisco; cAIDS & Cancer Specimen Resource,
SFGH
Oral Session:
Translational Studies. KSHV
Malignancies Associated with HIV/AIDS
Date:
July 2, 2015
Title:
Manocept, a Novel CD206 Targeting Agent
for Potential Use in Treatment of Kaposi’s Sarcoma
Authors:
Rongzhen Zhanga, Frederick O. Copeb,
Joshua Walkerc, Ken Williamsc, Ekaterina Maidjia, Cheryl Stoddarta,
Paige M. Braccia, Michael S. McGratha* (*Presenter)
aUniversity of California San Francisco;
bNavidea/Macrophage Therapeutics; cBoston College
About NavideaNavidea Biopharmaceuticals, Inc. (NYSE MKT:
NAVB) is a biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics, and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150604006087/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024